Clinical trials: AML With Gene Mutations
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice
Prospective, multicenter study for the non-inferiority assessment of RAMD compared to GSS in determining the prognostic risk category according to ELN2022 for newly diagnosed AML patients on blood samples.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult, Acute Promyelocytic Leukemia
- Trial name
- RAMD (NCT07867704)
- Testing
- Bone marrow or peripheral blood withdrawal for test comparison
- Volunteers
- 75 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Myeloid
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.
- Trial name
- NCT00030186
- Testing
- CEP-701 60mg, Cep-701 80mg, Cep-701 40mg
- Volunteers
- 37 people
- Sponsor
- Cephalon
Acute Myeloid Leukemia, FLT3 Gene Mutation
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the efficacy of gilteritinib as induction therapy in FLT3-positive adult acute myeloid leukemia patients.
- Conditions
- Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML, Diagnosis
- Trial name
- NCT06667973
- Testing
- Gilteritinib
- Volunteers
- 80 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
The main trial is a double-blinded, placebo-controlled, randomized, phase III, multi-center trial in adult patients with relapsed or refractory AML harboring an activating FLT3 mutation as defined in the inclusion /exclusion…
- Trial name
- NCT02298166
- Testing
- chemotherapy (Mitoxantrone, Cytarabine), Crenolanib, Allogeneic stem cell transplantation
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- University of Ulm
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors
Avapritinib in CBF-AML With KIT Mutations
AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate the efficacy of Avapritinib, an highly…
- Trial name
- NCT05821738
- Testing
- Avapritinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer.
- Trial name
- NCT01385150
- Testing
- mutation analysis, protein analysis, laboratory biomarker analysis
- Volunteers
- 220 people
- Sponsor
- Eastern Cooperative Oncology Group
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia With Gene Mutations
Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib
An expanded access program (EAP): Allows doctors to give medicine to patients, Before it is approved by health authorities. This EAP is for: Quizartinib Patients with FLT3-ITD mutated AML, AML that has come back, or Is resistant…
- Trial name
- NCT03746912
- Testing
- Quizartinib Dihydrochloride
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia With Gene Mutations, Adult Acute Myeloid Leukemia in Remission
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation.
- Trial name
- NCT02723435
- Testing
- Midostaurin
- Sponsor
- Stanford University
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission.
- Conditions
- Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia
- Trial name
- NCT04062266
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Acute Myeloid Leukemia
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who…
- Trial name
- NCT06549790
- Testing
- NMS-03597812
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- Nerviano Medical Sciences
Acute Myeloid Leukemia (AML)
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations.
- Trial name
- NCT05756777
- Testing
- Gilteritinib, Ivosidenib, Enasidenib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
This phase IB/II trial studies the best dose of TP-0903 and how well it works when given alone or with azacitidine in treating patients with FLT3 gene mutated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT04518345
- Testing
- Azacitidine, Dubermatinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Uma Borate
AML (Acute Myeloid Leukemia)
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults.
- Trial name
- NCT07751991
- Testing
- CHM-029
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Charm Therapeutics
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH…
- Trial name
- NCT04764474
- Testing
- HMPL-306
- Where
- 15 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- Hutchmed
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05024994
- Testing
- E7820
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it…
- Trial name
- NCT03793478
- Testing
- Quizartinib, Fludarabine, Cytarabine
- Where
- 27 sites in United States, Belgium and 8 more
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy, Temperature-Sensitive p53 Mutation
- Trial name
- NCT04906031
- Testing
- Sodium stibogluconate
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Jinan University
Acute Myeloid Leukaemia (AML)
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome
Acute Myeloid Leukemia (AML) arises from the somatic acquisition of genetic alterations in hematopoietic progenitor or stem cells.
- Trial name
- NCT07379528
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Newly Diagnosed AML With FLT3 Activating Mutations
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3…
- Trial name
- NCT02283177
- Testing
- crenolanib, cytarabine, daunorubicin
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Arog Pharmaceuticals, Inc.